Moderna, Inc. (MRNA) · Sep 1, 2026 · New debt

Moderna closes upsized $3B convertible debt deal, limiting dilution but adding leverage

$3.0B convertible debt — $3.0B 0.00% notes due 2032; 47.5% conversion premium

The financing brings in nearly $3B at zero interest, with capped calls cushioning dilution. The key terms were already known before closing.

The closing confirms a financing the market already knew was coming. Moderna completed the previously announced offering on September 1, 2026, exercising the full $400 million upsizing option; the August 28 pricing release had already disclosed the $2.6 billion base deal, the option, and the expected closing date.

ItemFinal termsComparison / implication
Principal raised$3.0B$2.6B base offering plus $400M option
Coupon0.00%No regular cash interest
MaturityMarch 1, 2032Long-dated obligation
Conversion price~$210.58/share47.5% above $142.77 reference price
Shares initially underlying notes14.25MMaximum 21.01M in limited circumstances
Net proceeds~$2.957BAfter discounts, expenses, and full upsizing
Capped-call cost$328.8MIntended to reduce dilution up to a $392.62 cap price

The structure is relatively shareholder-friendly on immediate dilution, but it still adds a substantial future obligation. The notes carry no regular interest and convert at a price well above the August 27 stock price, while the capped calls are designed to offset dilution below their cap. 〔0〕 However, conversion could still create as many as 21.0 million shares in specified circumstances, and the company owes $3.0 billion at maturity if the notes are not converted or otherwise settled. 〔1〕

The cash gives Moderna flexibility, not a newly disclosed operating catalyst. After spending $328.8 million on the capped calls, the company expects to use the remaining proceeds for general corporate purposes, including potential oncology investment and debt repayment. The filing does not commit the proceeds to a specific acquisition, program, or debt retirement, so the strategic payoff remains dependent on how management deploys the capital.

Net read: confirmation, not a fresh beat or miss. The completed deal is larger than the original August 27 proposal, but the upsized $2.6 billion pricing and full $400 million option were already public before this filing. Relative to the standing expectation immediately before the 8-K, the filing mainly formalizes the transaction: neutral information content, with low-cost funding and dilution protection balanced against added leverage and potential equity issuance.

Original filing on SEC EDGAR

More Moderna, Inc. news

Moderna closes upsized $3B convertible debt deal, limiting dilution but adding leverage | MRNA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.